- \n
- MALDI Biotyper\u00ae<\/sup> (MBT): Launch of proprietary MBT Easy T\u00ae<\/sup> Kit for consistent sample transfer to MALDI target plates<\/i><\/b><\/li>\n
- MALDI Biotyper\u00ae<\/sup>: Expansion of reference libraries to more than 5,300 species, spanning bacteria, yeasts, filamentous fungi, and mycobacteria<\/i><\/b><\/li>\n
- MALDI Biotyper\u00ae<\/sup>: Early KOL access to a novel cloud\u2011based identification solution, enabling identification against several specialist, expert\u2011curated libraries<\/i><\/b><\/li>\n
- MALDI Biotyper\u00ae<\/sup>: Ongoing broad, multi\u2011year clinical and translational study programs advancing automation, potential future claims, and next\u2011generation analytics, including:<\/i><\/b>\n
- \n
- IVDR-compliant clinical validation studies evaluating automated sample preparation workflows, covering both colony\u2011based cultures (MBT PrepMatic\u2122) and positive blood cultures (MBT SepsiMatic\u00ae<\/sup>)<\/i><\/b><\/li>\n
- U.S. clinical studies intended to support upcoming identification claims for mycobacteria and filamentous fungi, with FDA submission targeted for 2026<\/i><\/b><\/li>\n
- Ongoing clinical evaluation of MBT FAST, a rapid phenotypic antimicrobial susceptibility testing approach, aiming to enable IVDR-compliant same\u2011day results from positive blood cultures and agar colonies for Enterobacteriaceae<\/i><\/b><\/li>\n
- Exploratory, data\u2011driven research studies presented at ESCMID, including AI\u2011based antibiotic resistance prediction for Staphylococcus aureus, derived from large MALDI Biotyper spectral datasets<\/i><\/b><\/li>\n<\/ul>\n<\/li>\n
- IR Biotyper\u00ae<\/sup>: Enhanced outbreak detection with IR Tracker for surveillance of hospital\u2011acquired infections (HAIs) and new classifiers for Salmonella Typhi, STEC, and Shigella sp. detection<\/i><\/b><\/li>\n
- MBioSEQ\u2122 Ridom Typer: New software version, including TB\u2011Profiler antimicrobial resistance (AMR) determination, and GAMBIT bacterial species identification supporting MALDI \/ IR Biotyper\u00ae<\/sup>-triggered WGS reflex testing workflows,<\/i><\/b>with result application performed under laboratory responsibility<\/i><\/b><\/li>\n
- Introduction of Molzym as a part of Bruker Microbiology and Infection Diagnostics<\/i><\/b><\/li>\n<\/ul>\n
MUNICH–(BUSINESS WIRE<\/a>)–
\nAt ESCMID Global 2026<\/a>, Bruker<\/a> announces important portfolio enhancements across microbial identification, outbreak analysis, and reflex next\u2011generation sequencing (NGS) typing. These latest developments underscore Bruker\u2019s continued commitment to advancing integrated, high\u2011performance solutions that support laboratories in addressing evolving infectious disease challenges.<\/p>\nThis press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20260417265432\/en\/<\/a><\/p>\n
![\"MBT](\"https:\/\/mms.businesswire.com\/media\/20260417265432\/en\/2776836\/4\/MBT_Kit.jpg\")
<\/p>\nMBT Easy T\u00ae Kit \u2013 Bruker\u2019s consumables kit providing ready\u2011to\u2011use solvents and sample applicators for streamlined sample preparation in MALDI Biotyper\u00ae\u2011based microbial identification<\/p>\n<\/div>\n
MALDI Biotyper\u00ae<\/sup> Workflow and Identification Enhancements<\/b><\/p>\n
\nTo further streamline routine MALDI\u2011TOF workflows, Bruker introduces the proprietary MBT Easy T\u00ae<\/sup> Kit (RUO and IVDR), a consumables kit designed to simplify and standardize sample transfer steps to MALDI target plates. The kit includes ready-to-use reagents and applicators, supporting up to 2,000 samples, while enabling room temperature storage and reducing chemical waste.<\/p>\n
\nIn parallel, Bruker expands its MALDI Biotyper\u00ae<\/sup> reference libraries to more than 5,300 species, including bacteria, yeasts, filamentous fungi, and mycobacteria (RUO). The latest library updates add more than 600 new species and significantly strengthen species coverage, particularly for the dedicated filamentous fungi MyT workflow which benefits from ~30% stronger species coverage. Corresponding IVDR\u2011registered library expansions are currently in progress.<\/p>\n
\nTo extend access to specialized identification content beyond local installations, Bruker is offering early access to a cloud\u2011based MALDI identification solution (RUO) for selected key opinion leaders and expert laboratories. This approach enables research use identification using specialist libraries curated by domain experts, within the MBT Compass HT environment. Initial expert libraries include yeast collections, anaerobic bacteria libraries developed by academic partners, and mosquito libraries supporting malaria vector monitoring and research. The cloud infrastructure allows visibility of library provenance and provides a foundation for future capabilities such as exclusive libraries, online system monitoring, and software updates.<\/p>\n
\nBruker continues to advance automation across sample preparation workflows with MBT PrepMatic\u2122 and MBT SepsiMatic\u00ae<\/sup> systems, both currently under evaluation in IVDR-compliant clinical validation studies. MBT PrepMatic\u2122 is designed to enable semi\u2011 to fully automated colony picking from Petri dish cultures and preparation of MALDI target plates. MBT SepsiMatic\u00ae <\/sup>is designed to support a fully automated workflow from positive blood culture bottles to prepared MALDI target plates, with the potential to produce purified samples containing viable cells for downstream analysis.<\/p>\n
Advanced Clinical and Research Applications<\/b><\/p>\n
\nBruker is progressing multiple advanced applications for MALDI\u2011based microbiology. In the United States, clinical studies are underway to support upcoming claims for mycobacteria and filamentous fungi identification, with FDA submissions planned for 2026.<\/p>\n
\nClinical validation studies are underway on rapid phenotypic antimicrobial susceptibility testing (AST) using MALDI\u2011TOF MS, aimed at enabling same\u2011day results from positive blood cultures and agar colonies for Enterobacteriaceae<\/i>. This approach explores the use of machine\u2011learning\u2011based growth assessment and aligns conceptually with CLSI\u2011 and EUCAST\u2011guided broth microdilution principles.<\/p>\n
\nAt ESCMID Global 2026, Bruker is also presenting poster data from exploratory research on AI\u2011driven antibiotic resistance prediction for Staphylococcus aureus<\/i>, with AUROC >0.8, based on more than 2,600 MALDI Biotyper\u00ae<\/sup> spectra (RUO). Further studies with expanded scope are ongoing.<\/p>\n
Hospital Hygiene and Outbreak Management<\/b><\/p>\n
\nIn the area of hospital hygiene and epidemiology, Bruker expands IR Biotyper\u00ae<\/sup> applications (GP) with IR Tracker for surveillance of hospital\u2011acquired infections (HAIs) and new classifiers for clinically and epidemiologically significant organisms. Newly supported targets include Salmonella<\/i> Typhi, Shiga toxin\u2011producing E. coli<\/i> (STEC), and Shigella<\/i> species – pathogens associated with specific treatment requirements, high infectivity, and public health reporting obligations. These enhancements support rapid differentiation and classification to aid outbreak detection and infection control efforts.<\/p>\n
Reflex NGS and Culture\u2011Independent Diagnostics<\/b><\/p>\n
\nBruker introduces a new software version of its MBioSEQ\u2122 Ridom Typer (RUO), featuring short and long read whole genome sequencing (WGS) data analysis for research and expert laboratory applications. The software now includes TB-Profiler-based antimicrobial resistance (AMR) determination and GAMBIT bacterial species identification, supporting MALDI \/ IR Biotyper\u00ae<\/sup>-triggered WGS reflex workflows as part of laboratory\u2011defined analysis processes.<\/p>\n
\nIn addition, Bruker announces the integration of Molzym following its acquisition in late 2025, further strengthening the company\u2019s Microbiology & Infection Diagnostics portfolio. Molzym brings expertise in culture\u2011independent pathogen diagnostics, including its unique and patented MolYsis\u2122 host\u2011DNA depletion technology, which selectively removes host DNA to enable highly sensitive detection of microbial DNA in low\u2011biomass and blood samples for subsequent sequencing analysis.<\/p>\n
\n\u201cIn routine MALDI\u2011TOF identification, having critical reagents readily available in a standardized format is essential,\u201d said Kirsten Sch\u00f6nfeld, Diplom-Biologin, Institut Dr. Nowak GmbH, Germany. \u201cThe MBT Easy T\u00ae<\/sup> Kit provides pre\u2011filled, ready\u2011to\u2011use solvent ampoules, including formic acid, which will simplify logistics and daily laboratory operations. This helps maintain a robust and streamlined MALDI Biotyper workflow in a clinical setting.\u201d<\/p>\n
\nDr. Wolfgang Pusch, President of Bruker\u2019s Microbiology & Infection Diagnostics Division, added: \u201cFeedback like this underscores why we continue to invest in practical innovations that strengthen everyday laboratory workflows. Across microbial identification and outbreak analysis, Bruker is pursuing a broad and sustained innovation initiative – significantly expanding our reference libraries, introducing new sample preparation options to enable the highest level of standardization, and advancing exploratory artificial\u2011intelligence\u2011based approaches for antibiotic resistance prediction from MALDI spectra. In parallel, we are driving the development of automation for sample preparation from both colonies and positive blood cultures, initiating clinical studies for MALDI Biotyper\u00ae<\/sup>\u2011based rapid antimicrobial susceptibility testing, and further expanding the analytical capabilities of the IR Biotyper\u00ae<\/sup>. At the same time, we continue to refine our NGS\u2011based MBioSEQ\u2122 Ridom Typer , including ongoing, research\u2011use\u2011focused enhancements for tuberculosis antimicrobial resistance profiling.\u201d<\/p>\n
About Bruker Corporation \u2013 Leader of the Post-Genomic Era <\/b>(Nasdaq: BRKR)<\/p>\n
\nBruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker\u2019s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com<\/a>.<\/p>\n
<\/p>\n
View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260417265432\/en\/<\/a><\/span><\/p>\n
Trade Press & Customer Contact:
\n<\/b>
Alessandro Abramo
\n
Director Marketing & Product Management
\n
Bruker Microbiology & Infection Diagnostics Division
\n
T: +39-348-360-9058
\n
E: alessandro.abramo@bruker.com<\/a><\/p>\nInvestor Contact:
\n<\/b>
Joe Kostka
\n
Director, Investor Relations & Corporate Development
\n
Bruker Corporation
\n
T: +1 (978) 313-5800
\n
E: Investor.Relations@bruker.com<\/a><\/p>\n\n\u00a0<\/p>\n
KEYWORDS:<\/b> Germany Europe<\/p>\n
INDUSTRY KEYWORDS:<\/b> Biotechnology Technology Health Pharmaceutical Semiconductor Health Technology Research Infectious Diseases Software Science Clinical Trials<\/p>\n
- U.S. clinical studies intended to support upcoming identification claims for mycobacteria and filamentous fungi, with FDA submission targeted for 2026<\/i><\/b><\/li>\n
- MALDI Biotyper\u00ae<\/sup>: Expansion of reference libraries to more than 5,300 species, spanning bacteria, yeasts, filamentous fungi, and mycobacteria<\/i><\/b><\/li>\n
![\"Photo\"](\"https:\/\/mms.businesswire.com\/media\/20260417265432\/en\/2776836\/3\/MBT_Kit.jpg\")
<\/td>\n<\/tr>\n![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20260417265432\/en\/772973\/3\/Bruker_logo.jpg\"){kind=logo}
<\/td>\n<\/tr>\n